A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma
A phase 3 trial of Palifermin in Multiple myeloma, run by Swedish Orphan Biovitrum, completed.
Overview
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma is a phase 3 interventional study registered as NCT00434161 by Swedish Orphan Biovitrum, with 281 participants recorded, started 2006-12 and reaching its primary completion in 2009-03. Interventions recorded: Palifermin before only, Placebo, Palifermin before and after. Conditions recorded: Multiple Myeloma.
Linked to the drug Palifermin because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialPalifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
Shares Palifermin, Sobi (Swedish Orphan Biovitrum) and the tag pipeline.
- TrialPalifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
Shares Palifermin, Sobi (Swedish Orphan Biovitrum) and the tag pipeline.
- TrialPacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
Shares Sobi (Swedish Orphan Biovitrum) and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialMeasurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Shares Multiple myeloma and the tag pipeline.